Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Adverse cutaneous reactions after COVID-19 vaccinations have increased, highlighting not only how SARS-CoV-2 infection but also COVID-19 vaccines may induce adverse cutaneous manifestations. We evaluated the clinical and pathologic spectrum of mucocutaneous reactions after COVID-19 vaccinations, observed consecutively within three large tertiary centers of the Metropolitan City of Milan (Lombardy), comparing our results with the currently available literature. We retrospectively reviewed medical records and skin biopsies of patients diagnosed with mucocutaneous adverse events after COVID-19 vaccinations and followed at three Italian tertiary referral centers in the Metropolitan City of Milan. One hundred twelve patients (77 women and 35 men (112 total); median age, 60 years) have been included in the present study; a cutaneous biopsy was performed in 41 cases (36%). The trunk and arms were the most involved anatomic areas. Autoimmune reactions after COVID-19 vaccinations, urticaria, morbilliform eruptions, and eczematous dermatitis have been the most commonly diagnosed disorders. Compared to the currently available literature, we performed many more histologic examinations, allowing us to make more precise diagnoses. Most of the cutaneous reactions were self-healing and/or responded to topical and systemic steroids and systemic antihistamines, thus not discouraging the general population from carrying out vaccinations, which currently have a good safety profile.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970914PMC
http://dx.doi.org/10.1016/j.clindermatol.2023.02.001DOI Listing

Publication Analysis

Top Keywords

covid-19 vaccinations
20
reactions covid-19
16
clinical pathologic
8
pathologic spectrum
8
spectrum mucocutaneous
8
mucocutaneous reactions
8
vaccinations three
8
tertiary referral
8
referral centers
8
adverse cutaneous
8

Similar Publications

The chimpanzee adenovirus-vectored vaccine developed by the University of Oxford (ChAdOx1 nCoV-19) showed good stability when stored in refrigerator. However, the vaccine manufacturer prefers its transportation in frozen condition. Data regarding the stability of the vaccine after exposure to repeated freezing processes have not been explored yet.

View Article and Find Full Text PDF

Background: Among pregnant and postpartum women, decision-making for receiving the COVID-19 vaccine is influenced by vaccine safety concerns, misconceptions, shifting vaccine policies, and exclusion in the initial vaccine rollout. This caused confusion and vaccine hesitancy among many groups including pregnant and postpartum women.

Objective: The objective of this study was to understand the multilevel factors that influence vaccine decision-making among pregnant and postpartum women in Pakistan, which is crucial for improving vaccine demand among the vulnerable group-pregnant and postpartum women.

View Article and Find Full Text PDF

Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.

J Am Coll Cardiol

September 2025

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region of China; Advanced Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region of China

Background: There is no consensus for using statins for primary prevention of cardiovascular disease (CVD) and all-cause mortality in adults with type 1 diabetes mellitus (T1DM), because no randomized controlled trial has exclusively investigated statins in this population.

Objectives: In this study, the authors sought to evaluate the long-term risks and benefits of statins for primary prevention in adults with T1DM.

Methods: We performed a sequential target trial emulation comparing statin initiation vs noninitiation using UK primary care data from the IQVIA Medical Research Data database.

View Article and Find Full Text PDF

Pediatric bronchiectasis action management plan to improve clinical outcomes: An RCT.

Chest

September 2025

Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; School of Nursing and Midwifery, Charles Darwin University, Darwin, Northern Territory, Australia.

Background: Managing bronchiectasis exacerbations is a priority for patients/parents/caregivers of children with bronchiectasis, yet evidence-based strategies among the pediatric population remain limited.

Research Question: Does the use of a personalized, written bronchiectasis action management plan (BAMP), compared to standard care, reduce non-scheduled doctor visits among children/adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis?

Study Design And Methods: Our multicenter, double-blind, superiority, randomized controlled trial enrolled children from three Australian respiratory departments between June 2018 and December 2020. Children/adolescents aged <19 years with CSLD/bronchiectasis were randomized to receive a personalized BAMP (intervention) or standard care (controls).

View Article and Find Full Text PDF

Background: Chronically ill are advised to receive annual vaccinations against Covid-19 and seasonal influenza. Furthermore, chronically ill show an increased prevalence of comorbid common mental disorders (CMDs), like depression, anxiety, and somatoform disorders. With vaccination rates remaining insufficient among these vulnerable patients, prior research assumes an association between CMDs and vaccination readiness.

View Article and Find Full Text PDF